Immuneering Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Immuneering sono diminuiti a un tasso medio annuo di -27.6%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 19.3%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 69%.

Informazioni chiave

-27.6%

Tasso di crescita degli utili

14.9%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	-69.0%
Rendimento del capitale proprio	-100.6%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Ripartizione dei ricavi e delle spese

Come Immuneering guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGM:IMRX Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	0	-58	17	45
30 Jun 24	0	-56	17	44
31 Mar 24	0	-54	16	43
31 Dec 23	0	-53	17	42
30 Sep 23	0	-52	16	40
30 Jun 23	0	-52	16	39
31 Mar 23	0	-51	16	37
31 Dec 22	0	-51	16	36
30 Sep 22	1	-48	15	34
30 Jun 22	1	-44	13	31
31 Mar 22	2	-40	11	30
31 Dec 21	2	-34	8	27
30 Sep 21	3	-29	6	23
30 Jun 21	3	-24	4	22
31 Mar 21	3	-20	4	18
31 Dec 20	2	-17	3	15
31 Dec 19	2	-8	3	4

Guadagni di qualità: IMRX al momento non è redditizia.

Margine di profitto in crescita: IMRX al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: IMRX non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 27.6% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di IMRX nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: IMRX non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: IMRX ha un Return on Equity negativo ( -100.6% ), in quanto al momento non è redditizio.

Immuneering Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Third quarter 2023 earnings released: US$0.43 loss per share (vs US$0.49 loss in 3Q 2022)

First half 2023 earnings released: US$0.93 loss per share (vs US$0.93 loss in 1H 2022)

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.49 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Immuneering Corporation Announces Positive Initial Phase 2A Data Including Complete and Partial Responses with Imm-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell Small Cap Comp Value Index

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting

Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations

Independent Chair recently bought US$123k worth of stock

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Price target decreased by 12% to US$16.86

Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Share price stability

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Revenue and earnings growth

Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.43 loss per share (vs US$0.49 loss in 3Q 2022)

New minor risk - Share price stability

Immuneering Corporation Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

First half 2023 earnings released: US$0.93 loss per share (vs US$0.93 loss in 1H 2022)

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

New major risk - Revenue and earnings growth

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.49 loss in 1Q 2022)

Price target decreased by 12% to US$18.71

Consensus revenue estimates decrease by 80%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$21.33

Immuneering Corporation Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

Consensus revenue estimates fall by 26%

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer

Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering wins FDA nod to study lead asset in solid tumors

Immuneering Corporation Announces Committee Changes

Consensus forecasts updated

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2A Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immuneering Corporation Announces Management Changes

Immuneering initiated a Buy by Chardan, PT set to $18

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell 2500 Value Index

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

Immuneering Corporation, Annual General Meeting, Jun 21, 2022

Consensus revenue estimates fall by 75%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Immuneering Corporation Reports Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model

Immuneering Corporation (NasdaqGM:IMRX) acquired BioArkive, Inc. from Brett Hall, Praveen Nair, Daniel Flynn, Thomas Barr, Anna Travesa and Dennis Garland for $8.5 million.

Third quarter 2021 earnings released: US$0.47 loss per share

Director recently bought US$116k worth of stock

Director recently bought US$131k worth of stock

Less than half of directors are independent

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate